Ligand Pharmaceuticals

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Emeryville, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ligand Pharmaceuticals reports stellar Q4 earnings and growth prospects

Ligand Pharmaceuticals demonstrated robust financial performance in Q4 2022, driven by strong royalty revenue growth and strategic initiatives.
While facing challenges in cost optimization and label expectations, Ligand's focus on operational efficiency and growth opportunities positions it well for the future.
With a solid financial foundation, a diverse portfolio of assets, and a commitment to strategic growth, Ligand is poised for continued success and value creation.

Ligand Pharmaceuticals excels in Q1, eyes growth through strategic assets

Ligand Pharmaceuticals delivered robust Q1 results, positioning itself for continued growth and financial stability.
The company's strategic focus on high-quality assets, diversification, and efficient deal execution underscores its commitment to driving value for investors.
Despite market challenges, Ligand remains optimistic, leveraging opportunities in the biopharmaceutical sector to sustain growth and enhance shareholder value.

Ligand Pharmaceuticals excels in Q2, eyes strategic growth opportunities

Ligand Pharmaceuticals delivered a robust performance in Q2 2023, driven by strong revenue growth and strategic financial moves.
While facing challenges in contract revenue and competitive markets, Ligand's focus on key products and acquisitions signals resilience and adaptability.
Opportunities lie in expanding revenue streams, navigating market dynamics, and leveraging FDA developments for future growth.

Ligand Pharmaceuticals reports robust Q3 earnings and strategic investments

Ligand Pharmaceuticals showcased strong financial performance, strategic investments in late-stage products, and a focus on revenue growth and portfolio management. Despite challenges in clinical trials and market estimations, the company's emphasis on growth and investor engagement presents opportunities for future success.

Ligand Pharmaceuticals reports robust Q4 earnings and strategic growth moves

Ligand Pharmaceuticals showcased a strong financial performance in Q4 2023, with strategic business streamlining and portfolio enhancements driving growth. Despite supply constraints related to a predecessor product, successful collaborations have ensured manufacturing readiness for key products like Rylaze. The company's diversified portfolio and strong partnerships position it well for continued growth and shareholder returns in 2024.

Ligand Pharmaceuticals reports robust Q1 performance and strategic investments

Ligand Pharmaceuticals shows strong financial performance and growth potential, supported by strategic partnerships and key developments in their portfolio.
While facing challenges like upcoming generic competition and revenue uncertainty from recent deals, the company remains focused on long-term growth.
Opportunities lie in projected revenue and EPS growth, market expansion for Filspari, and continued interest in licensing for revenue diversification.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

NANJING, China and SAN DIEGO, June 2, 2021 /PRNewswire/ -- GenScript Biotech Corporation (HKG: 1548) along with its subsidiary, GenScript ProBio, and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that they have entered into a strategic licensing agreement for Ligand's OmniAb® Platform, a multi-species antibody discovery platform, to generate highly diversified, fully human antibodies that are optimized in vivo for immunogenicity, manufacturability and efficacy. Under terms of the agreement, GenScript is now able to offer its global customers access to the OmniAb rodent platforms for high-quality, rapid, fully human antibody discovery services.

GenScript Biotech and Ligand Pharmaceuticals Enter into Global OmniAb® Licensing Agreement

Ligand (LGND) reports mixed first-quarter 2021 numbers with earnings beating estimates but revenues missing the same. Stock down.

Ligand (LGND) Q1 Earnings Top, Bad Weather Hits Captisol Sales

Ligand Pharmaceuticals Incorporated (LGND) CEO John Higgins on Q1 2021 Results - Earnings Call Transcript

Shares of Ligand Pharmaceuticals (NASDAQ:LGND) fell 7% in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 58.43% over the past year to $1.41, which beat the estimate of $1.12.

Recap: Ligand Pharmaceuticals Q1 Earnings

SAN DIEGO--(BUSINESS WIRE)---- $LGND #earnings--Ligand Reports First Quarter 2021 Financial Results

Ligand Reports First Quarter 2021 Financial Results

Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ligand Pharmaceuticals (LGND) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

SAN DIEGO--(BUSINESS WIRE)---- $LGND #earnings--Ligand to Report First Quarter Financial Results on May 3, 2021

Ligand to Report First Quarter Financial Results on May 3, 2021

The Reddit crowd wasn't the only reason short-sellers got burned betting against this pharmaceutical company.

3 Signs the Ligand Short Squeeze Is Over

Unlike traditional biotech companies, Ligand's business model revolves around helping biotech companies to discover and develop medicines. Scalable platform technologies such as Captisol, OmniAb, Ion Channel Technologies and Pelican Expression, and a strong pipeline of partners, provide multiple pathways to growth.

Scalable Platform Business And Strong Pipeline Position Ligand For Long-Term Growth

On Friday, Ligand Pharmaceuticals got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96. The post Ligand Pharmaceuticals Joins Elite List Of Stocks With 95-Plus Composite Rating appeared first on Investor's Business Daily.

Ligand Pharmaceuticals Joins Elite List Of Stocks With 95-Plus Composite Rating

Ligand Pharmaceuticals saw its IBD SmartSelect Composite Rating jump to 96 Wednesday, up from 93 the day before. The post Ligand Pharmaceuticals Gets A Composite Rating Upgrade appeared first on Investor's Business Daily.

Ligand Pharmaceuticals Gets A Composite Rating Upgrade

Ligand (LGND) reported earnings 30 days ago. What's next for the stock?

Why Is Ligand (LGND) Down 21.3% Since Last Earnings Report?

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the appointment of Paul Maier as Non-Executive Director of the Board. Mr Maier will also be a member of 4D's Audit and Risk Committee and will serve as the Company's “audit committee financial expert” under SEC and Nasdaq rules. “With over 25 years of extensive senior operational,

4D Pharma Appointments Paul Maier to the Board as Non-Executive Director

Macerich

Mallinckrodt

Tanger Factory Outlet Centers

Short interest rates can be used to predict the potential direction of an individual stock. When stocks have a high short interest rate that's a good indicator that investors believe their share prices will decline soon.

Here Are The Stocks With The Highest Short Interest Rate

GameStop

iSun

Koss

Retail investors have been on the hunt for the most shorted stocks to buy in the market this week. Share prices have reached record levels due to a rally of short squeezes.

Stocks With The Highest Short Interest Rate: GameStop, ISun Inc

The unusual biotech could be a bitter pill for short sellers to swallow.

Forget Gamestop! This Highly Shorted Stock Is a Strong Buy Now

Ligand (LGND) reports better-than-expected fourth-quarter 2020 numbers. The company raises outlook for 2021.

Ligand (LGND) Q4 Earnings & Sales Top, 2021 Guidance Raised

Ligand Pharmaceuticals Incorporated (LGND) CEO John Higgins on Q4 2020 Results - Earnings Call Transcript

Shares of Ligand Pharmaceuticals (NASDAQ:LGND) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share rose 128.17% over the past year to $1.62, which beat the estimate of $0.99.

Ligand Pharmaceuticals: Q4 Earnings Insights

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2020 and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 8:30 a.m. Eastern time to discuss this announcement and answer questions. “2020 was a stellar year for Ligand, and we are well positioned for an even better 2021. I am extremely proud of how well the team has met b

Ligand Reports Fourth Quarter and Full Year 2020 Financial Results

Travere Therapeutics

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that their ongoing pivotal Phase 3 DUPLEX Study of sparsentan in focal segmental glomerulosclerosis (FSGS) achieved its pre-specified interim FSGS partial remission of proteinuria endpoint (FPRE) after 36 weeks of treatment. Sparsentan, an investigational product candidate, demonstrated a statistically significant response on FPRE compared to the activ

Ligand Partner Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

Madrigal Pharmaceuticals

Nektar Therapeutics

The GameStop effect will soon come to biopharma, an usually heavily-shorted sector. Here's a list of three of biopharma's more heavily-shorted stocks.

Gamestopping Biopharma: These Three Stocks May See A Short Squeeze Soon

One Of The Most Shorted Names In Biotech: Ligand Pharmaceuticals

This week, Ligand Pharmaceuticals (NASDAQ:LGND) found itself at the center of unexpected attention. The second-most shorted company in the U.S. saw its shares rise from $120 to almost $200 as Reddit users sought the next GameStop (NYSE:GME) to squeeze.

Redditors Are Betting on a $600 Ligand Stock Short Squeeze

AMC Entertainment

Bed Bath & Beyond

National Beverage

FuboTV

Virgin Galactic

SunPower

The r/WallStreetBets community have now exposed a new trading tactic to the masses: targeting short positions (just as they did through the pumping of GameStop stocks). The question everyone's asking is: what other stocks can I squeeze for profits?

News for Ligand Pharmaceuticals Stock (LGND)